| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| ln Vitro |
- Coumarin-3-carboxylic Acid (as a ligand in metal complexes) exhibited antiproliferative activity against human cancer cell lines. Specifically, its samarium(III) [Sm(III)], gadolinium(III) [Gd(III)], and dysprosium(III) [Dy(III)] complexes were tested on HeLa (cervical cancer), MCF-7 (breast cancer), and HepG2 (hepatocellular cancer) cells. The Sm(III) complex showed the strongest activity: it inhibited HeLa cell proliferation with an IC50 of ~12 μM, MCF-7 cells with an IC50 of ~15 μM, and HepG2 cells with an IC50 of ~18 μM. The Gd(III) and Dy(III) complexes had moderate activity, with IC50 values ranging from 20–25 μM across the three cell lines. All complexes exhibited concentration-dependent inhibition of cell viability, and their antiproliferative activity was significantly higher than that of free Coumarin-3-carboxylic Acid (IC50 > 50 μM for all cell lines). [2]
|
|---|---|
| Cell Assay |
- Antiproliferative activity assay (MTT method) for Coumarin-3-carboxylic Acid metal complexes:
1. Cell culture: HeLa, MCF-7, and HepG2 cells were cultured in RPMI 1640 medium (supplemented with 10% fetal bovine serum and antibiotics) at 37°C in a 5% CO₂ incubator. Cells were seeded into 96-well plates at a density of 5×10³ cells per well and incubated overnight to allow adherence. 2. Drug treatment: Serial dilutions of Sm(III), Gd(III), Dy(III) complexes of Coumarin-3-carboxylic Acid (final concentrations: 5, 10, 15, 20, 25 μM) and free Coumarin-3-carboxylic Acid (final concentrations: 25, 50, 75, 100 μM) were added to the wells. A blank control group (medium only) and a negative control group (cells + medium) were set up. 3. Incubation and detection: After 48 hours of incubation, MTT solution (5 mg/mL) was added to each well and incubated for another 4 hours. The supernatant was removed, and dimethyl sulfoxide was added to dissolve formazan crystals. Absorbance was measured at 570 nm using a microplate reader. Cell viability was calculated as (absorbance of treatment group / absorbance of negative control group) × 100%, and IC50 values were derived from concentration-viability curves. [2] |
| References |
|
| Additional Infomation |
2-O-2H-chromene-3-carboxylic acid is a coumarin compound. Coumarin-3-carboxylic acid is a derivative of coumarin (a natural benzopyranone compound) with a carboxylic acid group at the 3-position. A simple synthetic method is reported in [1]: prepared by the Knoevenagel condensation reaction of Meldrum acid with an ortho-hydroxyaryl aldehyde or ketone. The reaction was carried out with ethanol as solvent, piperidine as catalyst, and refluxed for 2-4 hours; the yield was 75-85%. [1] The antiproliferative mechanism of the coumarin-3-carboxylic acid metal complex is thought to involve binding to DNA (through the coumarin ring and carboxylic acid group), interfering with DNA replication, thereby inhibiting cancer cell division. However, [2]
|
| Molecular Formula |
C10H6O4
|
|---|---|
| Molecular Weight |
190.1522
|
| Exact Mass |
190.027
|
| CAS # |
531-81-7
|
| PubChem CID |
10752
|
| Appearance |
White to off-white solid powder
|
| Density |
1.493g/cm3
|
| Boiling Point |
388.6ºC at 760mmHg
|
| Melting Point |
189-192 °C(lit.)
|
| Flash Point |
162.7ºC
|
| LogP |
1.491
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
14
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C(C(=O)O[H])=C([H])C2=C([H])C([H])=C([H])C([H])=C12)=O
|
| InChi Key |
ACMLKANOGIVEPB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H6O4/c11-9(12)7-5-6-3-1-2-4-8(6)14-10(7)13/h1-5H,(H,11,12)
|
| Chemical Name |
2-oxochromene-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~525.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2590 mL | 26.2950 mL | 52.5901 mL | |
| 5 mM | 1.0518 mL | 5.2590 mL | 10.5180 mL | |
| 10 mM | 0.5259 mL | 2.6295 mL | 5.2590 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
